BACKGROUND: Mannose-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) are key components of the lectin pathway of complement activation. Their serum concentrations show a wide interindividual variability. This study investigated whether the concentration of MBL and MASP-2 is associated with prognosis in pediatric patients with cancer. METHODS: In this retrospective multicenter study, MBL and MASP-2 were measured by commercially available ELISA in frozen remnants of serum taken at diagnosis. Associations of overall survival (OS) and event-free survival (EFS) with MBL and MASP-2 were assessed by multivariate Cox regression accounting for prognostically relevant clinical variables. RESULTS: In the 372 patients studied, median serum concentration of MBL was 2,808 microg/L (range, 2-10,060) and 391 microg/L (46-2,771) for MASP-2. The estimated 4-year EFS was 0.60 (OS, 0.78). In the entire, heterogeneous sample, MBL and MASP-2 were not significantly associated with OS or EFS. In patients with hematologic malignancies, however, higher MASP-2 was associated with better EFS in a significant and clinically relevant way (hazard ratio per tenfold increase (HR), 0.22; 95% CI, 0.09-0.54; P = 0.001). This was due to patients with lymphoma (HR, 0.11; 95% CI, 0.03-0.47; P = 0.003), but less for those with acute leukemia (HR, 0.35; 95% CI, 0.11-1.15; P = 0.083). CONCLUSION: In this study, higher MASP-2 was associated with better EFS in pediatric patients with hematologic malignancies, especially lymphoma. Whether MASP-2 is an independent prognostic factor affecting risk stratification and anticancer therapy needs to be assessed in prospective, disease-specific studies. Copyright 2009 Wiley-Liss, Inc.
BACKGROUND:Mannose-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) are key components of the lectin pathway of complement activation. Their serum concentrations show a wide interindividual variability. This study investigated whether the concentration of MBL and MASP-2 is associated with prognosis in pediatric patients with cancer. METHODS: In this retrospective multicenter study, MBL and MASP-2 were measured by commercially available ELISA in frozen remnants of serum taken at diagnosis. Associations of overall survival (OS) and event-free survival (EFS) with MBL and MASP-2 were assessed by multivariate Cox regression accounting for prognostically relevant clinical variables. RESULTS: In the 372 patients studied, median serum concentration of MBL was 2,808 microg/L (range, 2-10,060) and 391 microg/L (46-2,771) for MASP-2. The estimated 4-year EFS was 0.60 (OS, 0.78). In the entire, heterogeneous sample, MBL and MASP-2 were not significantly associated with OS or EFS. In patients with hematologic malignancies, however, higher MASP-2 was associated with better EFS in a significant and clinically relevant way (hazard ratio per tenfold increase (HR), 0.22; 95% CI, 0.09-0.54; P = 0.001). This was due to patients with lymphoma (HR, 0.11; 95% CI, 0.03-0.47; P = 0.003), but less for those with acute leukemia (HR, 0.35; 95% CI, 0.11-1.15; P = 0.083). CONCLUSION: In this study, higher MASP-2 was associated with better EFS in pediatric patients with hematologic malignancies, especially lymphoma. Whether MASP-2 is an independent prognostic factor affecting risk stratification and anticancer therapy needs to be assessed in prospective, disease-specific studies. Copyright 2009 Wiley-Liss, Inc.
Authors: F N J Frakking; N Brouwer; K M Dolman; J B M van Woensel; H N Caron; T W Kuijpers; M D van de Wetering Journal: Clin Exp Immunol Date: 2011-04-13 Impact factor: 4.330
Authors: Wei Hu; Bryan A Bassig; Jun Xu; Tongzhang Zheng; Yawei Zhang; Sonja I Berndt; Theodore R Holford; H Dean Hosgood; Brian Leaderer; Meredith Yeager; Idan Menashe; Peter Boyle; Kaiyong Zou; Yong Zhu; Stephen Chanock; Qing Lan; Nathaniel Rothman Journal: Environ Mol Mutagen Date: 2012-10-11 Impact factor: 3.216
Authors: Ferenc Fekete; Balázs Fadgyas; Éva Papp; Ágnes Szilágyi; Zoltán Prohászka; Brigitta Müller; Gábor Kovács Journal: Pathol Oncol Res Date: 2015-10-03 Impact factor: 3.201
Authors: Anna S Świerzko; Mateusz Michalski; Anna Sokołowska; Mateusz Nowicki; Łukasz Eppa; Agnieszka Szala-Poździej; Iwona Mitrus; Anna Szmigielska-Kapłon; Małgorzata Sobczyk-Kruszelnicka; Katarzyna Michalak; Aleksandra Gołos; Agnieszka Wierzbowska; Sebastian Giebel; Krzysztof Jamroziak; Marek L Kowalski; Olga Brzezińska; Steffen Thiel; Jens C Jensenius; Katarzyna Kasperkiewicz; Maciej Cedzyński Journal: Front Immunol Date: 2018-09-20 Impact factor: 7.561
Authors: Manal F Elshamaa; Hala Hamza; Naglaa Abd El Rahman; Soha Emam; Eman A Elghoroury; Tarek M Farid; Asmaa Zakareya Zaher; Mona H Ibrahim; Solaf Kamel; Doaa Abd El-Aziz Journal: Arch Med Sci Atheroscler Dis Date: 2018-12-15